Manufacturers to submit new drug application for accelerated approval of pacritinib for myelofibrosis with severe thrombocytopenia

Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The application will be based on the available data from the Company's completed Phase 3 PERSIST-1 and PERSIST-2 trials.

Source:

Biospace Inc.